Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18912278 | MIRDAMETINIB TREATMENT | October 2024 | December 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18780132 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | July 2024 | January 2025 | Allow | 6 | 0 | 0 | Yes | No |
| 18034296 | HDAC INHIBITOR SOLID STATE FORMS | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18033897 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND NUCLEOSIDE ANALOG | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18249783 | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTIC AGENTS SELECTIVELY TARGETING HIGHLY GLYCOLYTIC TUMOR CELLS AND METHODS THEREOF | April 2023 | February 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18032387 | METHOD FOR PRODUCING DIIMINOPYRROLE COMPOUND | April 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18192703 | ABIETANES AND METHODS OF MAKING AND USING THE SAME | March 2023 | December 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 18189380 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | March 2023 | February 2025 | Allow | 23 | 0 | 1 | Yes | No |
| 18184335 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18044791 | ISOCHROMAN COMPOUND | March 2023 | July 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18181965 | 2-AMINOTHIAZOLES DERIVATIVES AND METHOD OF PREPARATION THEREOF USING SUPER-PARAMAGNETIC IRON OXIDE NANOPARTICLES (SPIONS) | March 2023 | January 2025 | Allow | 23 | 1 | 1 | No | No |
| 18173426 | COMPOUNDS AS GLP-1R AGONISTS | February 2023 | March 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18020827 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18040667 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18004996 | Antiviral Heteroaryl Ketone Derivatives | January 2023 | January 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18004722 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | January 2023 | November 2025 | Allow | 34 | 1 | 0 | No | No |
| 18013685 | METHODS OF TREATMENT FOR MELANOMA | December 2022 | January 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18084380 | BRAF DEGRADERS | December 2022 | July 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 17925579 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17998800 | INHIBITION OF ARENAVIRUSES BY COMBINATIONS OF APPROVED THERAPEUTIC DRUGS | November 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17998546 | Piperazine Cyclic Ureas | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17913870 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17895273 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | August 2022 | March 2025 | Allow | 31 | 0 | 0 | No | No |
| 17798742 | NOVEL SALTS OF NILOTINIB AND POLYMORPHIC FORMS THEREOF | August 2022 | October 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17792757 | ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17758102 | PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY | June 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17786295 | TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS | June 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17783338 | NEW FYN AND VEGFR2 KINASE INHIBITORS | June 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17663716 | COMPOUNDS | May 2022 | April 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17777209 | COMBINATION DRUG | May 2022 | February 2026 | Abandon | 45 | 2 | 0 | No | No |
| 17755780 | OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | May 2022 | December 2025 | Allow | 43 | 2 | 0 | No | No |
| 17767596 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | April 2022 | September 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17764658 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | March 2022 | January 2025 | Allow | 34 | 0 | 0 | No | No |
| 17638741 | BENZIMIDAZOLE AND HYDROGENATED CARBAZOLE DERIVATIVES AS GPX4 INHIBITORS | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17637860 | PYRAZOLE DERIVATIVES AND USE THEREOF | February 2022 | January 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17675917 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | February 2022 | May 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17633209 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | February 2022 | May 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17632132 | 1H-[1, 2, 3]TRIAZOLO[4, 5-H] QUINAZOLINE COMPOUNDS ACTING AS PROTEIN KINASE INHIBITORS | February 2022 | January 2025 | Allow | 36 | 1 | 0 | No | No |
| 17577949 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17626904 | PYRROMETHENE-BORON COMPLEX, COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM, LIGHT SOURCE UNIT, DISPLAY, AND ILLUMINATION DEVICE | January 2022 | January 2026 | Allow | 49 | 2 | 1 | No | No |
| 17620782 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | December 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17619367 | COMBINATION FOR THE TREATMENT OF INFECTIONS CAUSED BY MYCOPLASMA GENITALIUM | December 2021 | January 2026 | Abandon | 49 | 2 | 0 | No | No |
| 17618767 | INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | December 2021 | February 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17615821 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | December 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17614751 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | November 2021 | January 2026 | Abandon | 49 | 2 | 1 | No | No |
| 17613221 | MESYLATE SALT OF PARA-TOPOLIN, COMPOSITIONS CONTAINING SAID SALT AND USE THEREOF | November 2021 | March 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17595567 | DIETARY BUTYRATE AND ITS USES | November 2021 | November 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17611527 | COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS | November 2021 | January 2026 | Abandon | 50 | 2 | 0 | No | No |
| 17609989 | SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | November 2021 | January 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17610037 | SMALL MOLECULE MODULATORS OF GUT BACTERIAL BILE ACID METABOLISM | November 2021 | October 2025 | Allow | 47 | 2 | 1 | No | No |
| 17608524 | PREPARATION FOR USE IN WEIGHT MANAGEMENT COMPRISING OMEGA-3 FATTY ACID SALTS AND BASIC AMINO ACIDS | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17608459 | COMPOUNDS INHIBITING TDG ACTIVITY | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17605808 | GINKGOLIDE B DERIVATIVE AND SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | October 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17604606 | METHODS OF TREATING NEUROCOGNITIVE DISORDERS, CHRONIC PAIN AND REDUCING INFLAMMATION | October 2021 | March 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17604226 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | October 2021 | December 2025 | Abandon | 50 | 0 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner KUCKLA, ANNA GRACE works in Art Unit 1626 and has examined 15 patent applications in our dataset. With an allowance rate of 40.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner KUCKLA, ANNA GRACE's allowance rate of 40.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KUCKLA, ANNA GRACE receive 0.93 office actions before reaching final disposition. This places the examiner in the 7% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by KUCKLA, ANNA GRACE is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +90.0% benefit to allowance rate for applications examined by KUCKLA, ANNA GRACE. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.